Clinical evaluation of the BD ProbeTec ™ Neisseria gonorrhoeae Q x Amplified DNA Assay on the BD Viper ™ System with XTR™ Technology

Barbara Van Der Pol, Stephanie N. Taylor, William Lebar, Thomas Davis, Deanna Fuller, Leandro Mena, Paul Fine, Charlotte A. Gaydos, David H. Martin, Edward W. Hook

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: The excellent sensitivity and specificity of commercially available nucleic acid amplification tests (NAATs) for the identification of Neisseria gonorrhoeae have been demonstrated. This study evaluated the performance of the BD ProbeTec N. gonorrhoeae Q x (GCQ) Amplified DNA Assay on the BD Viper System with XTR Technology in a multicenter study. Methods: Specimens were collected at 7 geographically diverse clinical sites from 1846 women and men attending sexually transmitted disease, family planning, and obstetrics and gynecology clinics. There were 1768 evaluable participants, 994 women and 774 men. GCQ results from female endocervical, self-collected vaginal, male urethral swab specimens, and male and female neat (unpreserved) urine specimens, as well as those obtained using the urine preservative transport (UPT) tube for the GCQ assay were compared with patient infected status (PIS). For each participant, PIS was determined based on the combined results from the reference assays Aptima Combo 2 ® (AC2) and BD ProbeTec ET GC Amplified DNA Assay (PT). Results: The sensitivity versus PIS for endocervical, vaginal, and female UPT urine, and female neat urine samples was 98.5%, 100.0%, 98.5%, and 96.9%, respectively; the specificity was 99.7%, 99.1%, 99.7%, and 99.5%, respectively. The sensitivity versus PIS for male urethral swabs and both male UPT and neat urine was 100.0%, with specificities of 99.1% for the urethral swab and UPT urine and 98.9% for the neat urine. The overall GCQ assay performance was not statistically different from that of AC2 or PT. Conclusions: The GCQ assay demonstrated performance characteristics comparable with other commercially available nucleic acid-based tests such as AC2 and PT. Vaginal swabs, endocervical swabs, urethral swabs, and urine specimens may all be used for gonorrhea screening.

Original languageEnglish
Pages (from-to)147-153
Number of pages7
JournalSexually Transmitted Diseases
Volume39
Issue number2
DOIs
StatePublished - Feb 2012

Fingerprint

Neisseria gonorrhoeae
Urine
Technology
DNA
Nucleic Acid Amplification Techniques
Gonorrhea
Family Planning Services
Sexually Transmitted Diseases
Gynecology
Nucleic Acids
Obstetrics
Multicenter Studies
Sensitivity and Specificity

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Clinical evaluation of the BD ProbeTec ™ Neisseria gonorrhoeae Q x Amplified DNA Assay on the BD Viper ™ System with XTR™ Technology. / Van Der Pol, Barbara; Taylor, Stephanie N.; Lebar, William; Davis, Thomas; Fuller, Deanna; Mena, Leandro; Fine, Paul; Gaydos, Charlotte A.; Martin, David H.; Hook, Edward W.

In: Sexually Transmitted Diseases, Vol. 39, No. 2, 02.2012, p. 147-153.

Research output: Contribution to journalArticle

Van Der Pol, Barbara ; Taylor, Stephanie N. ; Lebar, William ; Davis, Thomas ; Fuller, Deanna ; Mena, Leandro ; Fine, Paul ; Gaydos, Charlotte A. ; Martin, David H. ; Hook, Edward W. / Clinical evaluation of the BD ProbeTec ™ Neisseria gonorrhoeae Q x Amplified DNA Assay on the BD Viper ™ System with XTR™ Technology. In: Sexually Transmitted Diseases. 2012 ; Vol. 39, No. 2. pp. 147-153.
@article{967ac8fc9ada4e3ea37d444f173783e8,
title = "Clinical evaluation of the BD ProbeTec ™ Neisseria gonorrhoeae Q x Amplified DNA Assay on the BD Viper ™ System with XTR™ Technology",
abstract = "Background: The excellent sensitivity and specificity of commercially available nucleic acid amplification tests (NAATs) for the identification of Neisseria gonorrhoeae have been demonstrated. This study evaluated the performance of the BD ProbeTec ™ N. gonorrhoeae Q x (GCQ) Amplified DNA Assay on the BD Viper ™ System with XTR ™ Technology in a multicenter study. Methods: Specimens were collected at 7 geographically diverse clinical sites from 1846 women and men attending sexually transmitted disease, family planning, and obstetrics and gynecology clinics. There were 1768 evaluable participants, 994 women and 774 men. GCQ results from female endocervical, self-collected vaginal, male urethral swab specimens, and male and female neat (unpreserved) urine specimens, as well as those obtained using the urine preservative transport (UPT) tube for the GCQ assay were compared with patient infected status (PIS). For each participant, PIS was determined based on the combined results from the reference assays Aptima Combo 2 {\circledR} (AC2) and BD ProbeTec ™ ET GC Amplified DNA Assay (PT). Results: The sensitivity versus PIS for endocervical, vaginal, and female UPT urine, and female neat urine samples was 98.5{\%}, 100.0{\%}, 98.5{\%}, and 96.9{\%}, respectively; the specificity was 99.7{\%}, 99.1{\%}, 99.7{\%}, and 99.5{\%}, respectively. The sensitivity versus PIS for male urethral swabs and both male UPT and neat urine was 100.0{\%}, with specificities of 99.1{\%} for the urethral swab and UPT urine and 98.9{\%} for the neat urine. The overall GCQ assay performance was not statistically different from that of AC2 or PT. Conclusions: The GCQ assay demonstrated performance characteristics comparable with other commercially available nucleic acid-based tests such as AC2 and PT. Vaginal swabs, endocervical swabs, urethral swabs, and urine specimens may all be used for gonorrhea screening.",
author = "{Van Der Pol}, Barbara and Taylor, {Stephanie N.} and William Lebar and Thomas Davis and Deanna Fuller and Leandro Mena and Paul Fine and Gaydos, {Charlotte A.} and Martin, {David H.} and Hook, {Edward W.}",
year = "2012",
month = "2",
doi = "10.1097/OLQ.0b013e3182372fd8",
language = "English",
volume = "39",
pages = "147--153",
journal = "Sexually Transmitted Diseases",
issn = "0148-5717",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Clinical evaluation of the BD ProbeTec ™ Neisseria gonorrhoeae Q x Amplified DNA Assay on the BD Viper ™ System with XTR™ Technology

AU - Van Der Pol, Barbara

AU - Taylor, Stephanie N.

AU - Lebar, William

AU - Davis, Thomas

AU - Fuller, Deanna

AU - Mena, Leandro

AU - Fine, Paul

AU - Gaydos, Charlotte A.

AU - Martin, David H.

AU - Hook, Edward W.

PY - 2012/2

Y1 - 2012/2

N2 - Background: The excellent sensitivity and specificity of commercially available nucleic acid amplification tests (NAATs) for the identification of Neisseria gonorrhoeae have been demonstrated. This study evaluated the performance of the BD ProbeTec ™ N. gonorrhoeae Q x (GCQ) Amplified DNA Assay on the BD Viper ™ System with XTR ™ Technology in a multicenter study. Methods: Specimens were collected at 7 geographically diverse clinical sites from 1846 women and men attending sexually transmitted disease, family planning, and obstetrics and gynecology clinics. There were 1768 evaluable participants, 994 women and 774 men. GCQ results from female endocervical, self-collected vaginal, male urethral swab specimens, and male and female neat (unpreserved) urine specimens, as well as those obtained using the urine preservative transport (UPT) tube for the GCQ assay were compared with patient infected status (PIS). For each participant, PIS was determined based on the combined results from the reference assays Aptima Combo 2 ® (AC2) and BD ProbeTec ™ ET GC Amplified DNA Assay (PT). Results: The sensitivity versus PIS for endocervical, vaginal, and female UPT urine, and female neat urine samples was 98.5%, 100.0%, 98.5%, and 96.9%, respectively; the specificity was 99.7%, 99.1%, 99.7%, and 99.5%, respectively. The sensitivity versus PIS for male urethral swabs and both male UPT and neat urine was 100.0%, with specificities of 99.1% for the urethral swab and UPT urine and 98.9% for the neat urine. The overall GCQ assay performance was not statistically different from that of AC2 or PT. Conclusions: The GCQ assay demonstrated performance characteristics comparable with other commercially available nucleic acid-based tests such as AC2 and PT. Vaginal swabs, endocervical swabs, urethral swabs, and urine specimens may all be used for gonorrhea screening.

AB - Background: The excellent sensitivity and specificity of commercially available nucleic acid amplification tests (NAATs) for the identification of Neisseria gonorrhoeae have been demonstrated. This study evaluated the performance of the BD ProbeTec ™ N. gonorrhoeae Q x (GCQ) Amplified DNA Assay on the BD Viper ™ System with XTR ™ Technology in a multicenter study. Methods: Specimens were collected at 7 geographically diverse clinical sites from 1846 women and men attending sexually transmitted disease, family planning, and obstetrics and gynecology clinics. There were 1768 evaluable participants, 994 women and 774 men. GCQ results from female endocervical, self-collected vaginal, male urethral swab specimens, and male and female neat (unpreserved) urine specimens, as well as those obtained using the urine preservative transport (UPT) tube for the GCQ assay were compared with patient infected status (PIS). For each participant, PIS was determined based on the combined results from the reference assays Aptima Combo 2 ® (AC2) and BD ProbeTec ™ ET GC Amplified DNA Assay (PT). Results: The sensitivity versus PIS for endocervical, vaginal, and female UPT urine, and female neat urine samples was 98.5%, 100.0%, 98.5%, and 96.9%, respectively; the specificity was 99.7%, 99.1%, 99.7%, and 99.5%, respectively. The sensitivity versus PIS for male urethral swabs and both male UPT and neat urine was 100.0%, with specificities of 99.1% for the urethral swab and UPT urine and 98.9% for the neat urine. The overall GCQ assay performance was not statistically different from that of AC2 or PT. Conclusions: The GCQ assay demonstrated performance characteristics comparable with other commercially available nucleic acid-based tests such as AC2 and PT. Vaginal swabs, endocervical swabs, urethral swabs, and urine specimens may all be used for gonorrhea screening.

UR - http://www.scopus.com/inward/record.url?scp=84855829543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855829543&partnerID=8YFLogxK

U2 - 10.1097/OLQ.0b013e3182372fd8

DO - 10.1097/OLQ.0b013e3182372fd8

M3 - Article

C2 - 22249304

AN - SCOPUS:84855829543

VL - 39

SP - 147

EP - 153

JO - Sexually Transmitted Diseases

JF - Sexually Transmitted Diseases

SN - 0148-5717

IS - 2

ER -